Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-EN Version v1-EN
Language English English
Date Updated 2019-09-19 2019-09-11
Drug Identification Number 02016109 02016109
Brand name SURVANTA SURVANTA
Common or Proper name SURVANTA 8mL vial SURVANTA 8mL vial
Company Name ABBVIE CORPORATION ABBVIE CORPORATION
Ingredients BERACTANT BERACTANT
Strength(s) 25MG 25MG
Dosage form(s) SUSPENSION SUSPENSION
Route of administration INTRATRACHEAL INTRATRACHEAL
Packaging size 8mL vial (010401320) 8mL vial
ATC code R07AA R07AA
ATC description OTHER RESPIRATORY SYSTEM PRODUCTS OTHER RESPIRATORY SYSTEM PRODUCTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2019-09-10 2019-09-10
Actual start date 2019-09-10 2019-09-10
Estimated end date 2019-09-18 2019-09-18
Actual end date 2019-09-18
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments We are currently on managing our inventory for Survanta 8 mL due to an unexpected increase in market demand. Shall you not be in the position to wait until the predicted resolution date for your order, we do have normal inventory levels of Survanta 4 mL that can be provided instead. We are currently on back-order situation for Survanta 8 mL due to an unexpected increase in market demand. Shall you not be in the position to wait until the predicted resolution date for your order, we do have normal inventory levels of Survanta 4 mL that can be provided instead.
Health Canada comments